Advertisement

Topics

Orexo AB Company Profile

11:16 EDT 22nd June 2018 | BioPortfolio

We start by matching unmet patient needs with the unrealized potential in many existing compounds. We create novel pharmaceuticals, at lower development cost and risk, with shorter time to market.
The right time for a great concept
What if it were possible to take good drugs with high commercial value and make them even better? Not just through minor reformulations or patent extensions, but by adding innovative properties that really benefit patients? This is precisely what a Swedish physician and his colleagues asked themselves in 1995 when they founded Orexo.
Since then, Orexo has become a progressive, fast-growing pharmaceutical company. We’re product-focused, not platform-driven, and we have a proven track record.
Our approach is to develop proprietary pharmaceuticals to address areas of unmet therapeutic need. We do this by using a stepwise synergy process: First we assess areas of need. Then we work to meet the need by combining existing substances with our proprietary drug delivery technologies and unique expertise in dry pharmaceutical formulations.

Location

P.O. Box 303
Uppsala
SE-751 05
Sweden

Contact

Phone: 46 (0)18 780 88 00
Fax: 46 (0)18 780 88 88
Email: info@orexo.se


News Articles [9 Associated News Articles listed on BioPortfolio]

Orexo (ORX) - Profitability continues

Edison Investment Research - Pharmaceutical & healthcare - Orexo: Orexo reported an operational quarter in line with guidance. Total revenues of SEK139.7m in Q118 represented an increase of about 10% ...

Orexo (ORX) - EU launch milestone achieved

Edison Investment Research - Pharmaceutical & healthcare - Orexo: Yesterday Orexo announced the launch of Zubsolv in the EU by its partner Mundipharma, triggering a €3m (c SEK30.6m) milestone pay...

Mundipharma launches Zubsolv in EU, Orexo to get EUR 3 million milestone payment

Orexo AB announces that its partner Mundipharma has initiated the launch of Zubsolv (buprenorphine and naloxone sublingual tablet), for use in the treatment of opioid dependence, in the EU.

Management tracks: Axcella, Arcturus, Orexo

Orexo AB ADR 2018 Q1 - Results - Earnings Call Slides

Orexo AB ADR 2017 Q4 - Results - Earnings Call Slides

Zubsolv® Now Launched in the EU, Which Triggers a EUR 3m Milestone Payment to Orexo

     (Logo: https://mma.prnewswire.com/media/707203/Orexo_Logo.jpg) It is estimated that there are approximately 1.3 million high-risk opioid users in Europe. [1]Although estimates vary signifi...

Orexo letar finanschef

Läkemedelsbolaget letar ny finanschef efter att Henrik Juuel beslutat lämna bolaget.

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Efficacy and Safety Study of BLX-028914 in Subjects With Allergic Rhinitis

This is a phase II study in patients with seasonal allergic rhinitis (SAR) and will compare the effect versus placebo of two different oral doses of BLX-028914 in an allergen challenge mod...

Companies [1 Associated Companies listed on BioPortfolio]

Orexo AB

We start by matching unmet patient needs with the unrealized potential in many existing compounds. We create novel pharmaceuticals, at lower development cost and risk, with shorter time to market. The...

More Information about "Orexo AB" on BioPortfolio

We have published hundreds of Orexo AB news stories on BioPortfolio along with dozens of Orexo AB Clinical Trials and PubMed Articles about Orexo AB for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Orexo AB Companies in our database. You can also find out about relevant Orexo AB Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record